Immunization and Innovation: The Role of Vaccination in Reducing the Threat of Emerging Infectious Diseases

Elkin Vladimir Lemos Luengas
Department of Biostatistics and Data Science, University of Texas Health Science Center at Houston (UTHealth Houston), Houston, Texas, USA
Correspondence to: lemoselkin4@gmail.com

DOI: https://doi.org/10.70389/PJPH.100016

Additional information

• Ethical approval: N/a
• Consent: N/a
• Funding: No industry funding
• Conflicts of interest: N/a
• Author contribution: Elkin Vladimir Lemos Luengas – Conceptualization, Writing – original draft, review and editing
• Guarantor: Elkin Vladimir Lemos Luengas
• Provenance and peer-review:
  Commissioned and externally peer-reviewed
• Data availability statement: N/a

Keywords: Emerging infectious diseases, Vaccine innovation, mRNA technology, Global health partnerships, Vaccine equity.

Peer Review
Received: 1 November 2024
Revised: 20 November 2024
Accepted: 24 November 2024
Published: 18 December 2024

Introduction

Background and Rationale

Emerging infectious diseases (EIDs) are a persistent threat to global public health, affecting morbidity, ­mortality, and the economy. Because such diseases are often suddenly emerging, and may rapidly transnationally manifest, they require an effective response system to reduce their social and health impacts. We have seen epidemics like COVID-19, Zika, Ebola, and bird flu develop over the past few years, making effective public health interventions such as vaccines essential.¹ The determinacy of EIDs because of urbanization, climate change, and travel globally makes proactive prevention strategies even more important.² Vaccination has historically been one of the most effective critical tools for controlling infectious diseases. Viral therapy directly reduces infection and indirectly gives herd immunity, allowing vaccines to keep many pathogens in check and prevent disease outbreaks. Global efforts to fight diseases such as measles and hepatitis B, for example, have shown how high vaccination rates can reduce disease and mortality.³ Even more importantly, the World Health Organization’s Immunization Agenda 2030 (IA2030) promotes vaccination as a cornerstone of a global health strategy that will prevent millions of deaths in the next 10 years through better immunization coverage and novel vaccine delivery systems.⁴

In response to EIDs, improved vaccines have made responses quicker. Technologies like mRNA platforms and reverse vaccinology enable the quick creation of vaccines from target identification to mass production, dramatically decreasing the time it takes for pathogens to be discovered and immunized.² mRNA vaccines’ success in the COVID-19 pandemic, for example, has created a blueprint for quickly responding to infectious threats in the future.⁴ Other vaccine delivery technologies, such as nanoparticle vaccines and thermostable vaccines, aim to distribute vaccines to resource-poor communities, accelerating universal vaccination.¹ It gives a quick overview of the fundamental role that vaccination plays in EID prevention, and how emerging technologies are changing the face of immunization. By comparing vaccines in the market, technology advances, and delivery issues related to vaccination, this article aims to demonstrate how innovation and ­collaboration are crucial for combating EIDs. We will discuss the ­history of public health vaccination, the latest technological breakthroughs, issues that plague current immunization efforts, and where we can go from here in order to ensure a robust and holistic response to new infectious threats in the following sections.

Methodology

The aim of this review is to collect, evaluate, and synthesize the literature on new vaccines against novel infectious diseases. Even though it is a narrative review, certain steps were taken to provide as much coverage as possible and minimize bias. The process is explained in the steps below:

Literature Search: A structured search was conducted across a variety of databases, including PubMed, Scopus, and Web of Science, for publications between 2020 and 2024. The keywords were “emerging infectious diseases,” “vaccine innovation,” “vaccine equity,” and “public health partnerships.” We threw in peer-reviewed articles, systematic reviews, and the latest vaccine technology.

Inclusion and Exclusion Criteria: These studies were chosen for their up-to-date relevance: They looked at global health effects, vaccine challenges, and emerging technologies. The rules of exclusion included obsolete articles, studies that did not focus on immunization or infectious disease, and unreviewed sources.

Data Extraction: It pulled key findings and information from each article: study goals, findings, and conclusions on vaccination for new infectious diseases. The results were divided into topics such as vaccine innovation, access issues worldwide, and public health approaches.

Synthesis and Analysis: The extracted data were combined to determine patterns, issues, and holes in the current vaccinating paradigm. Comparative analysis was employed to identify disparities in vaccine availability between low- and high-resource contexts, with an emphasis on public health effects.

Limitations: This is a narrative review, so some of the drawbacks are selection bias because of the manual selection of studies and the absence of quantitative analysis.

Main Sections

The Impact of New Infectious Diseases

New infectious diseases EIDs are diseases whose prevalence has increased in the past few decades, or may continue to rise in the coming years, and pose grave threats to human health and global security. These illnesses tend to be a result of an intricate interplay between environmental changes, global movement, and zoonotic transfer from animal reservoirs to the host. The most prominent are COVID-19, Zika virus, Ebola, and recently mpox (formerly monkeypox), all of which have underlined the broader impact of EIDs on society, economies, and healthcare.5

What are EIDs and Primary Examples?

EIDs tend to be the result of pathogens that either are novel to human beings or have evolved to be more infectious, transmittable, or virulent. Table 1 lists the most common EID examples, as well as transmission paths and impacts. Of these, the most critical of these is COVID-19 – a pandemic caused by SARS-CoV-2 – which has implications for health, economy, and society around the world.

Table 1: Overview of Key Emerging Infectious Diseases, Transmission Modes, and Impact.
Disease	Pathogen	Year(s) Emerged	Transmission	Key Impact
SARS	SARS-CoV	2003	Respiratory droplets	High mortality, contained by public health interventions
H1N1	Influenza A	2009	Respiratory droplets	Global pandemic with moderate mortality
Ebola	EBOV	2014, 2018, 2021	Bodily fluids	High mortality in West Africa
Zika	Zika virus	2015–2016	Mosquito-borne	Associated with birth defects
COVID-19	SARS-CoV-2	2019–present	Respiratory droplets	Global pandemic with severe economic and social impact
Mpox	Mpox virus	2022–present	Close contact, zoonotic	Spread to non-endemic regions, declared PHEIC in 2024
Note:Data compiled from Bloch et al (2024), Cabezas and Vasconcelos (2024), Celik et al (2023), Liao et al (2024), Nasir (2024), and Mpox-PHEIC-Editorial (2024).

Likewise, Zika caused massive alarm over the association of major birth defects, and Ebola outbreaks have contributed to massive mortality in Africa, showing that regional outbreaks can rapidly evolve into national crises.^6,7

What Drives the Increase in EIDs?

Globalization and Urbanization

Globalization and the spread of individuals and goods have also made it easier for pathogens to penetrate across borders. Due to urbanization, cities are often crowded, without adequate sanitation or health services, and therefore, the rates of transmission are higher.⁷ Such dense cities offer perfect opportunities for germs to infect humans – as in SARS and COVID-19.

Climate Change: Changes in climate affect how mosquitoes, the vectors of dengue, Zika, and chikungunya, spread. Temperatures and altered rainfall patterns extend vector species’ ranges and bring diseases to new regions.⁸ A warming climate can also trigger zoonotic spillovers, in which pathogens migrate from the animal to the human, in environments impacted by habitat destruction.

Environmental Invasion and Zoonotic Disturbance: As deforestation, cropping, and urbanization have increased, the rift between people and animals has grown. This intrusion places human beings closer to animal reservoirs, and thus more vulnerable to zoonotic transmission. Species-hopping viruses such as mpox, which originated in African wildlife reserves, have overcome species boundaries in these environments, becoming a perennial global health issue.⁹

Health, Economy, and Society Effects of EIDs: EIDs put financial pressure on medical systems — sustaining outbreaks requires huge investment, from hospital emergency rooms to longer-term intensive care. Economistically, pandemics usually wasted human capital, disrupted commerce, and escalated the cost of healthcare (as in the COVID-19 pandemic that wiped out the entire world’s GDP). Socially, pandemics sabotage daily lives, leaving their victims psychologically stressed and anxious for life.⁷ EIDs’ challenges emphasize preventative strategies like immunization. Fast response times – such as in the COVID-19 pandemic – are because of improvements in vaccine technology such as mRNA technology. When vaccines are being developed and campaigns are being launched for diseases like mpox, we see that public health infrastructure and disease surveillance continue to need to be funded.¹⁰ Our global community will need to focus its resources on the EID threat, more aggressive surveillance, research on vaccines, and long-term public health. They are necessary to stop new outbreaks in their tracks and save societies from the hellish impact of EIDs.

History and Future Effect of Vaccination on New Infectious Diseases: Vaccination remains one of the most powerful public health programs, proven effective in preventing disease and saving millions of lives. There are very early examples, for example, the smallpox vaccine devised by Edward Jenner in 1796, which became the basis for current immunization programs, and eventually ended smallpox across the world in 1980. This feat was the proof of vaccine efficacy in thwarting and eliminating diseases, and it shaped subsequent vaccine programs for a wide range of infectious diseases.¹¹

Key Historical Achievements in Vaccination

Global smallpox elimination is the most famous instance of vaccination at work. The World Health Organization (WHO) set out to eradicate it with a warped program in 1966, using mass vaccination and surveillance to suppress epidemics. Not only did this program complete smallpox elimination in 1980, but it was also the model for future disease eradication programs.¹² Polio is another example of the effectiveness of vaccination to eliminate a once-omnipresent pathogen. After Albert Sabin developed the oral polio vaccine in 1960, the world lost polio by a whopping 73%. Since the creation of the Global Polio Eradication Initiative in 1988, wild poliovirus has been reduced to almost nonexistence with only a handful of endemic countries left. WHO predicts the eradication of all forms of polio in the near future, which is the second human pathogen eliminated by vaccine.¹³ In addition, WHO’s Expanded Programme on Immunization (EPI), issued in 1974, shows even more just how powerful vaccination has been as a public health weapon. In 2024, EPI alone is said to have prevented more than 154 million deaths in the world with vaccination campaigns against diphtheria, tetanus, pertussis, and measles. For instance, measles vaccination alone caused dramatic decreases in childhood mortality around the world, indicating the longevity of mass immunization programs.¹⁴

Case Reports of EIDs: New infectious diseases like COVID-19, Ebola, and mpox demonstrate how vaccines are now working against novel infections. Instigating worldwide vaccine development, the COVID-19 pandemic led to the emergence of mRNA vaccines in short order from companies such as Pfizer-BioNTech and Moderna. Such vaccines were highly effective in preventing serious cases and death, a technological triumph for vaccination. With COVID-19 vaccines being distributed worldwide, 19.8 million lives were saved in 2021 alone – showing the vaccine’s importance to pandemic response.¹⁴

Ebola, which was spreading mostly in West Africa, entered the world’s public sphere in 2014–2016 and proved that there was an urgent need for fast vaccines to contain outbreaks. The rVSV-ZEBOV vaccine created and used in the epidemic had been very successful in limiting the spread of the virus and decreasing the rates of transmission in subsequent outbreaks. This victory not only saved lives but also showed the power of vaccine-based interventions in reducing EIDs in high-risk areas.¹² Mpox or monkeypox, again returning, only served to show how vaccines were vital to the management of zoonotic diseases. When the WHO in 2022 designated mpox a public health emergency of international concern (PHEIC), more people got vaccinated – and often at high-risk groups. Vaccination campaigns with modified vaccinia Ankara vaccines, first invented for smallpox, helped control outbreaks in both endemic and non-endemic areas.¹⁰

Data on Vaccine Effectiveness

Vaccination has had a surprising quantitative impact on disease prevention and life expectancy. Recent estimates indicate that WHO’s EPI has helped to reduce infant mortality across the world, accounting for 40% of the global decrease in infant mortality in the last 50 years. This represents about 10.2 billion years of lifelong health saved through decreased mortality and morbidity because of vaccine-preventable diseases.¹³ Statistics on measles and polio vaccines reinforce the lifesaving value of vaccination. The global measles vaccine prevented some 25.5 million deaths between 2000 and 2023, and the polio vaccine saved thousands of paralysis and death. These successes prove that vaccines continue to be one of the most promising approaches to addressing the worldwide burden of disease and improving public health.¹¹ COVID-19 vaccines provide compelling evidence of the acute protective power of vaccination. In a model study of COVID-19 vaccination outcomes around the world, vaccines cut deaths in 2021 by around 60% relative to a vaccine-less case. This dramatic decline in mortality underscores the importance of vaccines to counteract EID effects in real time.¹²

Development and Technology of Vaccines’ Innovations in Vaccine Design and Technology

Similarly, the vaccinology industry is being transformed by emerging technologies that facilitate a quicker and comprehensive response to EIDs. Everything from mRNA platforms to viral vector technology to synthetic biology has helped accelerate vaccine development. Such advances — inspired by COVID-19 — laid the basis for future public health benchmarks for vaccine design, response, and resilience.

mRNA Technology

The technology of mRNA vaccines revolutionized the production and development of vaccines, particularly those against EIDs. This technique uses messenger RNA to activate cells to release a pathogen protein, prompting the immune system to react when the pathogen is not present. The world’s first mRNA vaccines, developed by Pfizer-BioNTech and Moderna for COVID-19, showed that mRNA platforms could generate vaccines of unprecedented efficacy at unprecedented rates. It was a quick and simple approach to manufacture and re-engineer, so researchers could adapt the vaccines as new SARS-CoV-2 strains were discovered.¹⁵ Efficiency is one of the most critical parameters in designing mRNA vaccines. Old-fashioned vaccines often begin by slowly loading viruses into cells or eggs. mRNA vaccines, however, are produced faster when the genome of the pathogen is fixed, and so there is less time between pathogen discovery and vaccine delivery. The estimates indicate that COVID-19 vaccines could be produced in a year using mRNA platforms, whereas the traditional vaccines take 5–10 years.¹⁶ And then there is the future of mRNA beyond COVID-19. Scientists are experimenting with mRNA vaccines for other viruses: flu, Zika, and even cancer. This versatility of mRNA vaccines and the recent development of Lipid Nanoparticle (LNP) delivery vehicles, which shield mRNA and enable it to enter cells, reflect the platform’s potential for broader applications.¹⁷

Viral Vector Platforms

Another new paradigm in vaccine design is viral vector technology. It works by using altered viruses to inject genes coding for an antigen from the target organism into human cells, which triggers an immune reaction. These include the AstraZeneca and Johnson & Johnson COVID-19 vaccines, which utilize adenovirus vectors. Virological vector vaccines are particularly effective for rapidly producing immunity, as was the case with Ebola outbreaks, where viral vector vaccine, rVSV-ZEBOV, contained epidemics in West Africa.¹⁸ These vector vaccines have been crucial in combating high-fatality, fast-tracking diseases. Viral vectors can instigate robust cellular immune responses and are particularly helpful against pathogens that demand this kind of immunity. We are still studying their capabilities in diseases like malaria and HIV where cellular immunity is crucial. Yet one of the most significant issues with viral vector vaccines is that already established resistance to the vector itself can make the vaccine ineffective in some populations.¹⁹

Synthetic Biology and Genomic Techniques

This is how synthetic biology and genomic engineering are now well-rounded ways to create vaccines. These techniques let researchers design novel antigens that produce robust immune reactions. DNA vaccines, another genomic approach – which involves introducing plasmid DNA encoding an antigen into host cells that release the antigen, leading to an immune response – are another. Preclinical trials of DNA vaccines for Zika and dengue have already been conducted, and those are promising for infections where conventional means fail.²⁰ Perhaps, most exciting of all are synthetic antigens, which are extremely similar to pathogenic proteins, which enable the immune system to identify the antigen and enhance the vaccine. It might also mean universal vaccines that can be administered against different versions of the same virus, and maybe no more regular updates (flu vaccines, for example).

Innovations in Vaccine Delivery Systems: Newer vaccine delivery systems also allowed the vaccine to be better accessed and distributed, particularly in underprivileged communities. New technologies for administration – nanoparticle vaccines, no-needle injectors, and thermostable medications – solve storage, transportation, and delivery problems.

Nanoparticle-Based Vaccines: Nanoparticles have a precise delivery mechanism through which vaccines can be delivered to specific cells and trigger the immune system. Nanoparticles such as LNPs, used for mRNA vaccines, protect the mRNA and promote uptake by cells. Nanocarriers also maintain vaccines and do not require cold storage, which is critical when sending vaccines to places with poor infrastructure.¹⁷

Needleless Delivery Systems: Needleless delivery systems like jet injectors and microneedle patches are the best replacement to injections. These are systems that help patients become more tolerant by decreasing needle anxiety and pain. Furthermore, microneedle patches can be self-infected, expediting mass vaccination in the event of a pandemic or outbreak by alleviating pressure on healthcare personnel.¹⁵

Thermostable Vaccines: Thermostability is an exciting development to allow vaccines to be stored and administered where refrigeration is scarce. Older vaccines usually require cold chain logistics for transportation and therefore are not available in villages. Immune vaccines that react at a higher temperature, which last longer, avoid refrigeration and minimize distribution. For example, scientists are working on thermostable COVID-19 vaccines to deliver in the tropics.18

Technologies and New Infectious Diseases’ Effects on New Diseases

World EID preparedness has vastly improved because of the new vaccine and delivery technologies. COVID-19 demonstrated how urgent vaccines need to be, and mRNA and viral vector vaccines’ pandemic triumph offered a path for the future. They are increasingly expensive as researchers consider their potential to be used to treat a growing range of infectious diseases. For instance, the current work in developing mRNA vaccines against other viral diseases, delivered through LNPs, may be able to deliver a mass scale-up response for the next pandemic. Synthetic biology is also a programmable mechanism for designing vaccines against previously unknown pathogens, improving our ability to combat new diseases as they arise. New mRNA technologies, virus vector systems, synthetic biology, and new delivery methods make vaccines more effective and efficient. These technologies are good tools for future pandemic preparedness and help support the need for more investments in vaccine research and development to keep the world safe.

Challenges and Limitations of Current Vaccination Strategies

Vaccination remains one of the most effective public health interventions, but its full potential is often hindered by challenges that limit equitable access and widespread uptake. The barriers to effective vaccine distribution and administration are multifaceted, involving logistical, social, and biological complexities that must be addressed to achieve global immunization goals (Figure 1).

Vaccine Hesitancy and Misinformation

Vaccine aversion is a public health nightmare driven by misinformation and even mistrust of health care. The COVID-19 pandemic only increased vaccine reticence as the speed at which vaccines were created raised questions about efficacy and safety in some populations. They often result from fake news that spreads easily through online sources. Researchers reported that this reluctance to take the COVID-19 vaccine extended to other vaccines, impacting vaccination rates for diseases such as measles and rubella that had been successfully managed with vaccination.²¹ Strategies to fight vaccine reluctance must include community engagement, open communication, and health education. Individualized campaigns, which involve local authorities and personalize messaging, were found to improve vaccine adoption, especially among marginalized groups. However, vaccine resistance is something that takes time and will always be funded through public health communication and education.²²

Logistical Challenges in Vaccine Distribution

Logistic problems, especially in Low- and Middle-Income Countries (LMICs), hamper vaccine availability. Vaccine storage, transport, and administration take an infrastructure that is not always well suited to resource-poor environments. Cold chain requirements that maintain vaccine efficacy are the real obstacle, with vaccines like mRNA COVID-19 vaccines requiring ultracold storage, hard to ensure in a region with little electricity and refrigeration. It is even more difficult in the rural or outlying areas, with a lack of transport network, making the timely provision of vaccines even harder.²³ Some health systems are trying to deal with these issues through digital health technologies like mobile health apps and electronic health records to better monitor and coordinate immunization. For instance, digital registries and vaccine tracking systems have helped track the spread of COVID-19 vaccines and pinpoint areas of low coverage. However, these solutions are expensive in terms of technology and training, and thus might not be affordable for all LMICs.²⁴

Global Access to Vaccines

Equity Problems

The global access to vaccines is an issue of equity worldwide. Vaccine equity is an issue as vaccines continue to be unreached all over the world. Larger countries get vaccines via advance purchase contracts, and LMICs have little access. Even as projects such as COVAX try to achieve a fair distribution, vaccine nationalism has repeatedly undone that, especially in the early years of the COVID-19 pandemic. This imbalance is not just a problem for COVID-19: It has also affected vaccines for viruses such as flu, which poor countries find it difficult to maintain stable immunization programs.²⁵ Even distributions of access are also complicated by socioeconomic status – income, education, and geographical region. For the people who live in lower-income neighborhoods, there is typically more difficulty obtaining the vaccine because of lack of access to care and ignorance of the vaccinations and their advantages. For equity, there are options for subsidies of vaccine prices, centralization of vaccine dispensers, and cooperation with local agencies for raising vaccination awareness and confidence.²⁶

Limitations of Current Vaccines

Vaccines in place today are effective but limited in their efficacy, effectiveness longevity, and adaptability to rapidly mutating pathogens. Most vaccines are very strong, and then you have to keep getting them (because it diminishes with age). This is especially true with COVID-19 vaccines, which had to be boosted with boosters to keep the vaccine effective against new strains. Rapidly mutating pathogens, including influenza and SARS-CoV-2, are always a challenge because the effectiveness of the vaccine can drop with the new version and new formulations are needed.²⁷ For some diseases, very powerful vaccines have been difficult to create because of the bacterium. For HIV and malaria, for example, life cycles are complicated or genetically so variable that long-lasting vaccines are hard to produce. Attempts to combat these now use mRNA and viral vector platforms, enabling faster adaptation to new variants and possibly more powerful immune responses. However, these are very young technologies that will need to be further investigated to ensure optimal performance and resiliency.

Moral and Transport Problems in Under-Resourced Environments

Ethical questions of vaccine distribution are important, especially in rural areas where access differences are larger. They do not have the infrastructure needed to run mass vaccination campaigns. The rural area might lack access to doctors, for instance, and vaccination centers might be located far from home. This geographical divide usually decreases vaccination rates and leaves populations at risk for outbreaks of vaccine-induced diseases. There are ethical issues also in prioritizing vaccine provision in the event of pandemics. The choice of who gets vaccinated first (hospital workers, old people, or patients with health conditions) is a matter of good judgment. Moreover, in some parts of the world, public health initiatives face cultural and religious resistance, stopping certain groups from taking part in vaccination programs. The solution to these ethical and logistical challenges includes trusting community leaders, ethically guided vaccine distribution, and culturally appropriative outreach.²⁷

The challenges and limitations of current vaccination strategies underscore the need for innovative approaches to enhance vaccine access, acceptance, and efficacy. Vaccine hesitancy, logistical obstacles, and issues related to equity and efficacy continue to impede the goal of universal immunization. Addressing these challenges will require a multifaceted approach that includes technological innovation, policy reforms, community engagement, and investments in health infrastructure, particularly in underserved regions. As the world continues to face EIDs, strengthening vaccination strategies through equitable distribution, effective communication, and advanced vaccine technologies is essential to improving global health outcomes and resilience against future pandemics.

Public Health Partnerships and Global Collaboration: What Is At Play?

Global public health relies on partnerships and collaborations that work to overcome vaccine development, delivery, and access issues. This shared responsibility became particularly evident in the COVID-19 pandemic that highlighted the need for aggregation of resources, open communication, and coordinated action from governments, drugmakers, and international organizations. Important alliances, including Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI), and the WHO’s COVAX initiative, reflect the power of shared action to support vaccine equity and public health protection around the world (Figure 2).

Vaccine Development and Supply Chain Partnerships

The Role of Collaborations

Governments, international organizations, and private sector partnerships for public health are crucial to addressing the immense budgets required for vaccine creation and delivery. Partnerships draw on cross-sectoral financial, technical, and scientific resources to ensure that vaccines can be effectively delivered in resource-constrained LMICs. For example, Gavi, the Vaccine Alliance, has increased vaccine access in LMICs by working in close collaboration with pharmaceutical manufacturers to procure cheap vaccine stocks by applying mechanisms such as advanced purchase commitments to spur vaccine production for poorly resourced markets.²⁸ CEPI’s contribution adds another touch to the cooperative model. CEPI was founded in 2017 and, as part of the COVID-19 pandemic, helped coordinate vaccine research and development around the world to accelerate manufacturing and get ready for mass release. Through collaboration between the private sector and academics, CEPI enabled the development of lifesaving vaccines within 1 year, demonstrating that cross-sector collaboration can shorten response times in health emergencies.²⁹

Encouraging Alliances in International Immunization Campaigns

A number of partnerships have established a precedent for global health. The alliance between Gavi and WHO and UNICEF via COVAX was an effort to ensure equitable vaccine access around the world. The COVAX system, spearheaded by WHO, CEPI, and Gavi, was built to ensure that everyone, regardless of their income, received COVID-19 vaccines. In pooling and coordinating vaccine supply, COVAX initially targeted low-income individuals and healthcare professionals, offering an infrastructure model that could be scaled up in subsequent pandemics.³⁰ The same goes for the Developing Countries Vaccine Manufacturers Network (DCVMN), which brings together international agencies and governments to support vaccine manufacturing in the developing world. Sharing knowledge and technical assistance, the DCVMN can also build local manufacturing capabilities that keep vaccines available to populations. This network highlights how partnerships can be used to build resilience over time by giving regions autonomy to develop and disseminate vaccines.³¹

Transparency, Disclosure, and Communication as a Trust Foundation

Transparency and timely data-sharing are vital to establishing public confidence and rapid coordinated action during outbreaks. Good data-sharing agreements enable timely information sharing, allowing governments and health agencies to monitor disease transmission, tweak vaccines, and raise resources as required. The Global Initiative on Sharing All Influenza Data (GISAID) is a successful data-sharing initiative that allows global genomic tracking of flu and SARS-CoV-2 variants in real time. Such platforms boost health interventions because they offer a common data source for countries to use to refine and modify their strategies in real time.²⁹ Communication plays an equally important role in building trust with the public and stakeholders. COVAX’s model was based on open allocation and reporting mechanisms so that vaccines could be evenly distributed and held accountable. Periodic reports from WHO and COVAX collaborators about vaccine safety and availability played an essential role in fostering public trust and reducing vaccine aversion. Sensible messaging also protects against disinformation and emphasizes the importance of vaccination in areas with low vaccine confidence.²⁸

Challenges: Despite the achievements of these alliances, there is still work to do to ensure universal access to vaccines and to maintain global health programs. Vaccine nationalism and uneven distribution, as seen during the COVID-19 pandemic, make it more important to have stronger international arrangements that address global health rather than national interests. The WHO-proposed International Pandemic Treaty would establish legally binding agreements for countries to pool resources and support faster responses to future pandemics, which would facilitate an equal response to pandemics around the world.³⁰ Furthermore, ongoing collaborations must address differences in local production capacities. LMICs can invest in the infrastructure and regulatory training necessary to allow more regions to manufacture their vaccines without dependence on outsiders. Initiatives like CEPI’s work to boost vaccine hubs in Africa signal the shift to increasingly self-reliant health systems that could greatly improve world preparedness and resilience to future pandemics.²³

Partnerships in global health play an integral part in overcoming challenges related to vaccine production, access, and availability. The successes of initiatives such as Gavi, CEPI, and COVAX illustrate how these collaborative models could bring together people, expertise, and technology to help save public health around the world. Increased data-sharing, ­transparency and communication, and decentralization of vaccine ­production will build resiliency in the face of future ­epidemics. By consolidating and advancing these intergovernmental structures, the world will be better able to tackle new infectious diseases and deliver universal healthcare (Figure 3).

New Directions: The Future of Vaccination and EID Prevention

Capacity to Procure Vaccines

As there are inequalities exposing low- and middle as new, novel EIDs threaten, we should build and release vaccines more responsively and adaptively, and be globally ready for these threats. While the COVID-19 pandemic brought home how critical it is to have rapid vaccine response and equal access, it also showed us that there is more to innovate and invest in. This chapter details what we are in store for a better vaccine strategy and EID management, better vaccine technology, better international partnership, and better ­response capability.

Investing in Next-Generation Vaccine Technologies

For EIDs to be successfully fought, scientists and public health officials will need to keep developing vaccines. Next-generation platforms, including mRNA and viral vector vaccines, have been extremely versatile, allowing us to respond quickly to pathogens such as SARS-CoV-2. The next steps should be to scale these platforms further, making them more durable, scalable, and easy to distribute so that they are accessible in low-resource environments. Synthetic biology also holds the potential to create universal or multivalent vaccines that target multiple strains or related pathogens in a single dose, which would decrease the number of boosters and costs to healthcare systems.³² Another emerging innovation is the ability to make vaccines inaccessible, especially in regions that lack adequate cold chain infrastructure. Thermostability makes vaccines indelibly hotter – minimizing refrigeration and extending access in areas with little or no resources. The delivery technologies include nanoparticles, needleless injectors, and other non-necessary forms of delivery, which might make a medication more accessible and help ensure that patients are enrolled, particularly for mass vaccines during pandemics.³³

Stimulating Global Health Preparedness and Monitoring Systems

Detection and rapid response are the key to reducing EID outbreaks. The global surveillance networks that track and broadcast infectious disease outbreaks live can ensure more effective responses to new threats. Open-source tools such as the Global Health Security Agenda and GISAID already enable genomic tracking and data exchange. Further investing in digital health systems and mobile surveillance could enhance low-resource nations’ ability to track, detect, and manage outbreaks locally before they spread globally.²⁸ A potential path forward is regional disease surveillance hubs where regions of countries could share data, respond, and utilize resources more efficiently. These hubs can reduce the time to action and streamline cross-border coordination for resolving EIDs. Implementing AI and machine learning for surveillance could also aid in predictive models of disease progression so that public health agencies can make more accurate decisions based on real-time data analysis.³⁴

Promoting Equitable Vaccine Distribution

Access to vaccines is one of the world’s greatest challenges. Better-off countries tend to have greater-income countries (LMICs) to outbreaks. Despite innovations in the development of fair vaccine distribution such as WHO, Gavi, and COVAX, problems remain. The next steps should be toward building a long-term sustainable model for access, including increasing local vaccine manufacturing capacity in LMICs so that we do not need to rely on foreign sources.³³ Creating regional manufacturing hubs, particularly in Africa and Asia, are an important first step toward self-reliance. CEPI and WHO’s recent investments in African vaccine factories pave the way for local capacity that would lessen the burden of transport and allow greater cross-regional dispensing. Public–private partnerships will help to fund these efforts and make sure they have resources to do their job. Such partnerships, combined with investments in health workforce training and infrastructure, can increase LMICs’ resilience against future EIDs.³²

Building Public Trust and Community Participation

Keeping people confident is the key to success with vaccination, and vaccine resistance remains a challenge in many areas. Communication that is culturally relevant and culturally relevant can build trust and allow for vaccination adoption. This can include communicating with local authorities, religious organizations, and health workers to give accurate information and to break misconceptions about vaccines. More people are also being reached via social media and online campaigns. Digital communication programs that use public communications to disseminate open science-based data can prevent misinformation and restore faith in vaccines’ power to eradicate EIDs. Furthermore, vaccine literacy programs must be promoted so that individuals can be taught effectively about the science of vaccines and the positive effects that they can have on personal and public health.²⁸ Future vaccines, EID prevention, are the future. If we spend on next-generation vaccines, upgrade global surveillance and health systems, provide equal access, and instill public trust, the world can better prepare for a healthier future. These measures will require ongoing commitment from governments, the private sector, and international organizations. As the world learns from the pandemics of the past, and replicates the successes of unified action, a truly collaborative approach will prove to be the key to preserving global health and achieving a sustainable future.

Final Conclusion

Infectious disease threats are real and growing, and this calls for a holistic, responsive approach to global health, in the form of vaccines developed, distributed, and made accessible to everyone. Every chapter of this discussion points to unique facets of what lies ahead in vaccination strategies and EID prevention, and paints a picture of a world where innovation, collaboration, and trust are paramount. Both past and present vaccination campaigns show how much vaccines have changed global health – from curing smallpox to quickly adapting to modern-day pandemics like COVID-19. However, as new infectious diseases keep popping up, vaccine technologies have to adapt. Advances in mRNA technology, virus vectors, and synthetic biology may provide tools for creating vaccines more rapidly and more adaptively, but they will take substantial investments in research, infrastructure, and workforce development to make these opportunities come true. Challenges still exist such as vaccine aversion, logistical and equity barriers, current vaccine efficacy, and long-term viability. They ask for an international response, a multidimensional response, one that is multi-economic and multicultural. Governments, private companies, and international organizations must work in concert, and successful campaigns like COVAX and CEPI show how codesign models enable vaccines to be delivered quickly and in a fair manner.

Next Generation

The formula for a long-term, successful vaccine will be three things: sustained technological advancements, strong global health infrastructure, and public participation. In the long run, we will need to invest in regional manufacturing hubs, a broader data-sharing infrastructure, and open communication to establish public trust. The commitment to fair access shou  ld go well beyond the time of emergencies, aiming for long-term immunization programs that take in underserved areas. Finally, the lessons of past and ongoing efforts demonstrate that the future of global health is dependent on a whole-of-care strategy – a system that is simultaneously scientific, cross-sectoral, and ethical. In this way, we can all prepare for and reduce the effects of future pandemics, providing the basis for health resilience across our world.

References

1 Carter A, Msemburi W, Sim SY, Gaythorpe KAM, Lambach P, Lindstrand A, et al. Modeling the impact of vaccination for the immunization Agenda 2030: deaths averted because of vaccination against 14 pathogens in 194 countries from 2021 to 2030. Vaccine. 2024;42(Suppl 1):S28-37.
https://doi.org/10.1016/j.vaccine.2023.07.033
 
2 Pagliusi S, Dennehy M, Kim H, Committee DAO. Vaccines, inspiring innovation in health. Vaccine. 2018;36(48):7430-7.
https://doi.org/10.1016/j.vaccine.2018.05.035
 
3 Pal M, Tariku F, Upadhyay D, Zende R. Current innovations in the diagnosis and immunization of emerging and re-emerging zoonoses. Am J Epidemiol Infect Dis. 2024;12(2):23-8.
https://doi.org/10.12691/ajeid-12-2-2
 
4 Casellas J, Chacon-Cruz E, Colombo F. New vaccine platforms: A conversation with the father of reverse vaccinology. Vaccines Beat. 2024;2:6-8.
 
5 Bloch EM, Sullivan DJ, Casadevall A, Shoham S, Tobian AAR, Gebo K. Applying lessons of COVID-19 and other emerging infectious diseases to future outbreaks. mBio. 2024;15(6):e0110924.
https://doi.org/10.1128/mbio.01109-24
 
6 Cabezas C, Vasconcelos PFC. Creciente amenaza de enfermedades emergentes y reemergentes: Arbovirus y enfermedades transmitidas por vectores en las Américas. Rev Per de Med Exp Salud Pública. 2024;41:4-6.
https://doi.org/10.17843/rpmesp.2024.411.13805
 
7 Çelik M, Acar U, Akgul F, Arslan Y, Ceylan MR. Threat of mpox (monkeypox) outbreak after the COVID-19 pandemic: are healthcare professionals ready for new psychological wars? J. Contemp Med. 2023;13(5):966-74.
https://doi.org/10.16899/jcm.1319280
 
8 Liao H, Lyon CJ, Ying B, Hu T. Climate change, its impact on emerging infectious diseases and new technologies to combat the challenge. Emerg Microbes Infect. 2024;13(1):2356143.
https://doi.org/10.1080/22221751.2024.2356143
 
9 Nasir T, Safdar M, Bibi S, Rehman SU, Ozaslan M. Emerging infectious diseases and their preventive measures. In ÖZASLAN M, ed. Current Studies in Health and Life Sciences 2024 [Internet] 2024;(pp. 1-22). ISRES.
 
10 Sah R, Apostolopoulos V, Mehta R, Rohilla R, Sah S, Mohanty A, et al. Mpox strikes once more in 2024: declared again as a public health emergency of international concern. Travel Med Infect Dis. 2024;61:102753.
https://doi.org/10.1016/j.tmaid.2024.102753
 
11 Montero DA, Vidal RM, Velasco J, Carreno LJ, Torres JP, Benachi OM, et al. Two centuries of vaccination: historical and conceptual approach and future perspectives. Front Public Health. 2023;11:1326154.
https://doi.org/10.3389/fpubh.2023.1326154
 
12 Kayser V, Ramzan I. Vaccines and vaccination: history and emerging issues. Hum Vaccin Immunother. 2021;17(12):5255-68.
https://doi.org/10.1080/21645515.2021.1977057
 
13 Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, et al. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet. 2024;403(10441):2307-16.
https://doi.org/10.1016/S0140-6736(24)00850-X
 
14 Kouhanjani F. Historical evolution and impact of immunization on public health. Immunome Res. 2024;20(1):100265.
 
15 Vecchio R, Gentile L, Tafuri S, Costantino C, Odone A. Exploring future perspectives and pipeline progression in vaccine research and development. Ann Ig. 2024;36(4):446-61.
 
16 Buckland B, Sanyal G, Ranheim T, Pollard D, Searles JA, Behrens S, et al. Vaccine process technology-A decade of progress. Biotechnol Bioeng. 2024;121(9):2604-35.
https://doi.org/10.1002/bit.28703
 
17 Souto EB, Blanco-Llamero C, Krambeck K, Kiran NS, Yashaswini C, Postwala H, et al. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives. Acta Biomater. 2024;180:1-17.
https://doi.org/10.1016/j.actbio.2024.04.010
 
18 Mubashir H, Asif N, Khalil M, Rasool U, Anees N, Mehar T, et al. Current trends in vaccine technologies: Innovations and challenges. In Alvi MA, Rashid M, Zafar MA, Mughal MAS, Toor SI, eds. Complementary and Alternative Medicine: Immunization/Vaccinology [Internet] 2024;(pp. 539-46). Unique Scientific Publishers.
https://doi.org/10.47278/book.CAM/2024.459
 
19 Phad V, Farhat Z, Prasad A, Kumar S. Newer approaches for viral vaccine development. In Sevda S, Kumar S, ed. Bioreactor Design Concepts for Viral Vaccine Production [Internet] 2024;(pp. 389-99). Elsevier Inc.
https://doi.org/10.1016/B978-0-443-15378-5.00021-8
 
20 Abdaal K, Batool A, Navid MT, Ahmed S, Ahmed S, Qazi AS, et al. Advancements in vaccination strategies: from historical milestones to modern innovations in viral disease prevention and public health. Res J Vet Pract. 2024;12(1):11-21.
https://doi.org/10.17582/journal.rjvp/2024/12.1.11.21
 
21 Higgins DM, O’Leary ST. A world without measles and rubella: Addressing the challenge of vaccine hesitancy. Vaccines. 2024;12(6):694.
https://doi.org/10.3390/vaccines12060694
 
22 Pennisi F, Genovese C, Gianfredi V. Lessons from the COVID-19 pandemic: promoting vaccination and public health resilience, a narrative review. Vaccines (Basel). 2024;12(8):891.
https://doi.org/10.3390/vaccines12080891
 
23 Ebulue CC, Ekkeh OV, Ebulue OR, Ekesiobi C. Leveraging machine learning for vaccine distribution in resource-limited settings: a synthesis of approaches. Int Med Sci Res J. 2024;4(5):544-57.
https://doi.org/10.51594/imsrj.v4i5.1120
 
24 Pavia G, Branda F, Ciccozzi A, Romano C, Locci C, Azzena I, et al. Integrating digital health solutions with immunization strategies: improving immunization coverage and monitoring in the post-COVID-19 era. Vaccines (Basel). 2024;12(8):847.
https://doi.org/10.3390/vaccines12080847
 
25 Jecker NS. Achieving global vaccine equity: The case for an international pandemic treaty. Yale J Biol Med. 2022;95:271-80.
 
26 Nogareda F, Gharpure R, Contreras M, Velandia M, Lucia Pacis C, Elena Chevez A, et al. Seasonal influenza vaccination in the Americas: progress and challenges during the COVID-19 pandemic. Vaccine. 2023;41(31):4554-60.
https://doi.org/10.1016/j.vaccine.2023.06.024
 
27 Trovato M, Sartorius R, D’Apice L, Manco R, De Berardinis P. Viral emerging diseases: challenges in developing vaccination strategies. Front Immunol. 2020;11:2130.
https://doi.org/10.3389/fimmu.2020.02130
 
28 Nunes C, McKee M, Howard N. The role of global health partnerships in vaccine equity: a scoping review. PLOS Glob Public Health. 2024;4(2):e0002834.
https://doi.org/10.1371/journal.pgph.0002834
 
29 Govindaraj R. Global health partnerships in contemporary world: An overview, orientation and evolution. Chettinad Health City Med J. 2024;13(1):92-8.
https://doi.org/10.24321/2278.2044.202416
 
30 Agyarko R, Al Slail F, Garrett DO, Gentry B, Gresham L, Kromberg MLK, et al. The imperative for global cooperation to prevent and control pandemics. In McNabb SJN, Shaikh AT, Haley CJ, ed. Modernizing Global Health Security to Prevent, Detect, and Respond 2024;(pp. 53-4). Elsevier Inc.
https://doi.org/10.1016/B978-0-323-90945-7.00019-1
 
31 Pagliusi S, Che Y, Dong S. The art of partnerships for vaccines. Vaccine. 2019;37(40):5909-19.
https://doi.org/10.1016/j.vaccine.2019.07.088
 
32 Ahata B, Akcapinar GB. CCHFV vaccine development, current challenges, limitations, and future directions. Front Immunol. 2023;14:1238882.
https://doi.org/10.3389/fimmu.2023.1238882
 
33 Billington J, Deschamps I, Erck SC, Gerberding JL, Hanon E, Ivol S, et al. Developing vaccines for SARS-CoV-2 and future epidemics and pandemics: applying lessons from past outbreaks. Health Secur. 2020;18(3):241-9.
https://doi.org/10.1089/hs.2020.0043
 
34 Okesanya OJ, Olatunji G, Manirambona E, Oluebube MM, Rasheed AA, Olaleke NO, et al. Synergistic fight against future pandemics: lessons from previous pandemics. Infez Med. 2023;31(4):429-39.
https://doi.org/10.53854/liim-3104-2
 
35 Ebulue C, Ebulue OR, Ekesiobi CS. Public-private partnerships in health sector innovation: Lessons from around the world. International Medical Science Research Journal. 2024;4(4):484-499. https://doi.org/10.51594/imsrj.v4i4.1051
https://doi.org/10.51594/imsrj.v4i4.1051

Cite this article as:
Lemos Luengas EV. Immunization and Innovation: The Role of Vaccination in Reducing the Threat of Emerging Infectious Diseases. Premier Journal of Public Health 2025;2:100016

Export to EndNote Export to Mendeley